Subsequently, in another study, which is the the PETACC-8 trial that included exclusively stage III CRC patients treated with adjuvant FOLFOX, revealed an association of HER2 alterations possessing shorter time to recurrence and OS, even after adjustments for multiple clinical and pathological factors [128]. Here, ERBB2 is linked to colorectal carcinoma.